Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Prostate cancer detection by prostate-specific antigen-based screening in the Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection.

Teishima J, Maruyama S, Mochizuki H, Oka K, Ikeda K, Goto K, Nagamatsu H, Hieda K, Shoji K, Matsubara A.

Can Urol Assoc J. 2014 May;8(5-6):E327-32. doi: 10.5489/cuaj.1715.

2.

Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis.

Hung AY, Levy L, Kuban DA.

Cancer J. 2002 Nov-Dec;8(6):440-4.

PMID:
12500852
3.

[Clinical value of prostate specific antigen screening in early detection of prostate cancer].

Hua LX, Qiao D, Song NH, Feng NH, Yang J, Zhang JX, Chen JG, Zhang W, Sui YG, Wu HF.

Zhonghua Zhong Liu Za Zhi. 2009 Sep;31(9):705-9. Chinese.

PMID:
20021870
4.
5.

A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.

Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK, Recker F, Kwiatkowski M.

Eur Urol. 2015 Oct;68(4):591-7. doi: 10.1016/j.eururo.2014.04.005. Epub 2014 Apr 18.

PMID:
24794075
6.

Prostate-specific antigen velocity and prostate cancer gleason grade and stage.

Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.

Cancer. 2007 Apr 15;109(8):1689-95.

7.
8.
9.

Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.

Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH Jr, Magnabosco WJ, Mauad EC, Carvalho AL.

BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x. Epub 2012 Aug 14.

10.

Should we replace the Gleason score with the amount of high-grade prostate cancer?

Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH.

Eur Urol. 2007 Apr;51(4):931-9. Epub 2006 Aug 15.

PMID:
16935413
11.

Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.

Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, Pavlovich CP, Schaeffer EM.

BJU Int. 2012 Oct;110(8):1122-8. doi: 10.1111/j.1464-410X.2012.10986.x. Epub 2012 Feb 28.

12.

Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.

Miyamoto S, Ito K, Miyakubo M, Suzuki R, Yamamoto T, Suzuki K, Suzuki K, Yamanaka H.

Prostate Cancer Prostatic Dis. 2012 Mar;15(1):75-86. doi: 10.1038/pcan.2011.47. Epub 2011 Oct 11.

PMID:
21986985
13.

Prostate biopsy: who, how and when. An update.

Djavan B, Milani S, Remzi M.

Can J Urol. 2005 Feb;12 Suppl 1:44-8; discussion 99-100. Review.

PMID:
15780165
14.

Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.

Beard CJ, Chen MH, Cote K, Loffredo M, Renshaw AA, Hurwitz M, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):19-24.

PMID:
14697416
15.

Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.

Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y, Humphrey PA, Roehl KA, Catalona WJ.

Urology. 2002 Sep;60(3):469-73; discussion 473-4.

PMID:
12350486
16.

Mass screening of prostate cancer in Changchun City of China.

Li X, Tsuji I, Kuwahara M, Zhang H, Wang H, Zhang L, Ji G, Zhao X.

Int Urol Nephrol. 2004;36(4):541-8.

PMID:
15787333
17.

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.

Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R.

Urology. 2001 Jan;57(1):83-90.

PMID:
11164149
18.

The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.

Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL.

BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x. Epub 2011 Nov 15.

19.

Prostate cancer in patients with screening serum prostate specific antigen values less than 4.0 ng/dl: results from the cooperative prostate cancer tissue resource.

Datta MW, Dhir R, Dobbin K, Bosland MC, Melamed J, Becich MJ, Orenstein JM, Kajdacsy-Balla AA, Patel A, Macias V, Berman JJ.

J Urol. 2005 May;173(5):1546-51.

PMID:
15821483
20.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768

Supplemental Content

Support Center